Effect of tamoxifen on immune functions

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Tamoxifen is a widely used endocrine therapy for breast cancer.
• Understanding its impact on the immune system is crucial for patient management.
• Previous studies have yielded mixed results regarding tamoxifen's immunomodulatory effects.

Purpose of the Study:

• To investigate the effects of tamoxifen on various immune function parameters in breast cancer patients.
• To determine if tamoxifen therapy alters cellular immunity and mitogen responses.

Main Methods:

• Ten breast cancer patients received tamoxifen (20 mg twice daily).
• Immune functions were assessed before and at 3, 6, and 12 months after therapy initiation.
• Evaluated parameters included rosette-forming cell counts, surface immunoglobulin-positive cells, and responses to phytohemagglutinin and concanavalin A.

Main Results:

• No consistent changes were observed in most immune parameters, including erythrocyte rosette-forming cell counts and responses to mitogens.
• A significant decrease in erythrocyte antibody rosette-forming cells was noted at 6 months.
• Active erythrocyte rosette-forming cells showed a significant decrease at 12 months.

Conclusions:

• Tamoxifen treatment did not induce significant alterations in the overall immune capacity of breast cancer patients.
• Specific immune cell subsets exhibited transient changes, but these did not indicate a generalized immunosuppression or enhancement.
• Further research may be warranted to explore the clinical significance of minor immune variations during tamoxifen therapy.